Search results
Results from the WOW.Com Content Network
A phosphodiesterase-4 inhibitor, commonly referred to as a PDE4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4) on cyclic adenosine monophosphate (cAMP). It is a member of the larger family of PDE inhibitors. The PDE4 family of enzymes are the most prevalent PDE in immune cells. They are predominantly ...
Roflumilast, sold under the brand name Daxas among others, is a medication used for the treatment of chronic obstructive pulmonary disease, [4] plaque psoriasis, [5] seborrheic dermatitis, [6] and atopic dermatitis. [5] It acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). [10] It has anti-inflammatory effects ...
Adibendan; Aminophylline; Aminophylline dihydrate; Amipizone; Apremilast; Arofylline; Atizoram; Befuraline; Bemarinone hydrochloride; Bemoradan; Benafentrine; Bucladesine
It showed reasonable efficacy for treating COPD, but side effects were problematic and it is unclear whether cilomilast will be marketed, or merely used in the development of newer drugs. [ 3 ] [ 4 ] Cilomilast is a second-generation PDE4 inhibitor with anti-inflammatory effects that target bronchoconstriction , mucus hypersecretion, and airway ...
Phosphodiesterase-5. A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
PDE4 inhibitor This page was last edited on 2 July 2022, at 11:15 (UTC). Text is available under the Creative Commons Attribution-ShareAlike 4.0 ...
Fluticasone propionate is broken down by CYP3A4 (cytochrome P450 3A4), and has been shown to interact with strong CYP3A4 inhibitors such as ritonavir and ketoconazole. [ 2 ] [ 3 ] Coadministration of ritonavir and fluticasone may lead to increased levels of fluticasone in the body, which may lead to Cushing's Syndrome and adrenal insufficiency ...
Formulations of delayed-release budesonide are an effective treatment for mild-to-moderately active Crohn's disease involving the ileum and/or ascending colon. [25] A Cochrane review found evidence for up to three months (but not longer) of maintenance of remission in Crohn's disease, concluding that budesonide is not effective for maintenance of remission in CD.